中/EN Contact/Message
  • Home
  • central pharmacy
  • Policies
  • Medical Institution
  • Franchise
  • Innovate
  • Recruit
  • News
  • Home
  • central pharmacy
  • Policies
  • Medical Institution
  • Franchise
  • Innovate
  • Recruit
  • News
  • 中/EN
  • Contact/Message
    • Innovate
    Your current position：
    Orserdu
    Orserdu
    departments：肿瘤科
    drug：片剂
    Active：elacestrant
    indication：在至少一线内分泌治疗后，治疗雌激素受体阳性、人类表皮生长因子受体2阴性、ESR1突变、晚期或转移性乳腺癌，并进行疾病进展
    Licensor：Stemline Therapeutics, Inc.
    Approved Country/Region：FDA
    Approval time：2023-01-27